Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Mitral Stenosis : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Multimedia
References

Related Articles
Cor Triatriatum




Patient Education
Click here for patient education.



Author: Senthil Nachimuthu, MD, Assistant Professor, Department of Medicine, Tulane University School of Medicine; Chief, Department of Medicine, Huey P Long Medical Center

Senthil Nachimuthu is a member of the following medical societies: American College of Physicians

Coauthor(s): Kiruthika Balasundaram, MBBS, Cardiac Outreach Program Director, Kovai Heart Foundation, India; Holger P Salazar, Jr, MD, FACC, Assistant Professor, Department of Medicine, Section of Cardiology, Tulane University Health Sciences Center; Medical Director, Cardiac Intensive Care Unit, Veterans Affairs Medical Center of New Orleans

Editors: L Michael Prisant, MD, FACC, Director of Hypertension Unit, Professor, Department of Internal Medicine, Medical College of Georgia; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Steven J Compton, MD, FACC, FACP, Director of Cardiac Electrophysiology, Alaska Heart Institute, Providence and Alaska Regional Hospitals; Amer Suleman, MD, Consultant in Electrophysiology and Cardiovascular Medicine, Department of Internal Medicine, Division of Cardiology, Medical City Dallas Hospital; Michael E Zevitz, MD, Assistant Professor of Medicine, Finch University of the Health Sciences, The Chicago Medical School; Consulting Staff, Private Practice

Author and Editor Disclosure

Synonyms and related keywords: mitral stenosis, mitral valve stenosis, MVS, chronic rheumatic disease, congenital mitral stenosis, systemic lupus erythematosus, SLE, rheumatoid arthritis, RA, metabolism disorder, congenital metabolic disorder, metabolic disorder, Fabry's disease, Fabry disease, Hurler-Scheie syndrome, valve calcification, mitral valve calcification, infective endocarditis, carcinoid syndrome, acute rheumatic fever, ARF, congestive heart failure, CHF, heart disease, cardiac disease, amyloid deposition, amyloid, tricuspid regurgitation, hemoptysis

Background

Mitral stenosis is an obstruction to left ventricular inflow at the mitral valve level because of structural abnormality of the mitral valve apparatus. Rheumatic fever is the main cause of mitral stenosis. Other etiologies are uncommon and include congenital mitral stenosis, such as parachute mitral valve or Lutembacher syndrome; rheumatologic conditions, specifically systemic lupus erythematosus and rheumatoid arthritis; inborn errors of metabolism (eg, Fabry disease, Hurler-Scheie syndrome); marked mitral annular calcification of the mitral valve; infective endocarditis with large vegetations (often fungal); and carcinoid syndrome. Sometimes, conditions such as left atrial myxoma can mimic mitral stenosis by obstructing outflow. Amyloid deposition in the mitral valve can also lead to mitral stenosis.

Only fewer than half of patients with mitral stenosis have a clear history of acute rheumatic fever due to the mild nature of the disease. Because no specific tests are available for the diagnosis of acute rheumatic fever, it is often misdiagnosed.

Stenosis of the mitral valve occurs after multiple attacks of acute rheumatic fever. Usually, 2 years to many decades elapse before mitral stenosis develops. More frequently, an acute episode of rheumatic fever causes mitral regurgitation instead of stenosis. Pathologically, multiple inflammatory foci (Aschoff bodies, ie, perivascular mononuclear infiltrate) develop in the endocardium and myocardium. Also, small vegetations are present along the border of the valves.

Over time, recurrent episodes of rheumatic fever worsen the insult, which typically leads to adhesion of the commissures, thickening and shortening of the chordae tendineae, thickening of the valve leaflets, and calcium deposition in the valve leaflets and/or the subvalvular apparatus. Slowly, the valve apparatus retracts and becomes stenotic and contracted. Whether the hemodynamic injury to the already affected valve apparatus or the chronic inflammatory rheumatic process leads to the progression of valvular damage remains unclear.

Pathophysiology

Normal mitral valve orifice area is approximately 4-6 cm2. As the orifice size decreases, an increasing pressure gradient across the mitral valve is required to maintain adequate flow (Bernoulli principle).

When the valve area is less than 2 cm2, patients may be asymptomatic at rest. However, moderate exercise or any factors that increase heart rate and cardiac output increase the mitral valve gradient and thus pulmonary wedge pressure, resulting in exertional dyspnea.

Severe mitral stenosis occurs with a valve area less than 1 cm2 as the resting diastolic mitral valve gradient raises above 20 mm Hg. This leads to transudation of fluid into the lung interstitium and decreased pulmonary compliance with dyspnea at rest or with minimal exertion. Hemoptysis may occur because of the rupture of lung venules. The raising pressure in the left atrium provokes its dilatation, which frequently results in the subsequent increased risk of atrial fibrillation, with subsequent left atrial appendage thrombus formation.

Normally, the mean pulmonary artery pressure is less than 25 mm Hg; when it exceeds 30 mm Hg, right ventricular function begins to decline. Pulmonary hypertension develops because of (1) backward transmission of left atrial pressure, (2) pulmonary arteriolar constriction, (3) interstitial edema, and (4) organic obliterative changes in the pulmonary vascular bed. These changes in the pulmonary vascular bed protect the pulmonary capillaries from the surge of blood passing into the capillaries during activity and thus from pulmonary congestion. As pulmonary hypertension increases, right ventricular dilation occurs, which leads to tricuspid regurgitation. Right ventricular failure leads to elevated jugular venous pressure, liver congestion, ascites, and pedal edema.

Left ventricular end-diastolic pressure and cardiac output are normal in persons with isolated mitral stenosis. However, associated significant mitral regurgitation, systemic hypertension, aortic stenosis, and myocardial infarction can affect left ventricular function and lead to decreased cardiac output.

Frequency

United States

The prevalence of rheumatic disease among persons in developed nations, such as the United States, is steadily declining. An estimated 1 in 100,000 people are affected.

International

The prevalence is higher in developing nations. In India, for example, the prevalence is approximately 100-150 cases per 100,000 people.

Mortality/Morbidity

  • The 10-year survival rate for asymptomatic persons is approximately 80%.
  • The 10-year survival rate for patients with mild symptoms is approximately 60%.
  • The 10-year survival rate among patients who develop congestive heart failure is 15%.

Sex

  • For reasons not clearly known, mitral stenosis is more common in females than in males. Nearly two thirds of patients with mitral stenosis are female.

Age

  • The onset of symptoms usually occurs between the third and fourth decade of life.



History

  • Symptoms of mitral stenosis usually develop in the third or fourth decade of life. Nearly half of the patients do not recall a history of acute rheumatic fever.
  • The rate of disease progression is fast in patients in developing countries and slow in patients in western countries.
  • The patient is generally asymptomatic in the early phase of the disease. However, factors that increase the heart rate precipitate dyspnea by increasing the gradient between the left atrium and the left ventricle. These factors include fever, severe anemia, thyrotoxicosis, sexual intercourse, exercise, excitement, pregnancy, and paroxysmal tachycardia.
  • As the disease progresses, the patient develops dyspnea upon exertion, orthopnea and paroxysmal nocturnal dyspnea, and atrial arrhythmia.
  • Nearly 15% of patients develop embolic episodes that are usually associated with atrial fibrillation. Rarely, embolic episodes have developed in patients with sinus rhythm.
  • Systemic embolization leads to stroke, renal failure, and myocardial infarction.
  • Hoarseness can develop from compression of the left recurrent laryngeal nerve by an enlarged left atrium against the pulmonary artery. Also, compression of bronchi by the enlarged left atrium can cause a persistent cough.
  • Hemoptysis may occur and is usually not fatal. It occurs because of the rupture of thin, dilated bronchial veins due to left atrial hypertension.
  • Pregnant women with mild mitral stenosis may become symptomatic during their second trimester because of the increase in blood volume.
  • Some patients present with chest pain, the reason for which is not clearly known. Most of the time, chest pain can be related to pulmonary hypertension, coronary embolization, or coronary atherosclerosis.

Physical

  • Patients may develop pinkish-purple patches (malar flush) on their cheeks, which usually correlates with severe mitral stenosis due to poor cardiac output and vasoconstriction.
  • The jugular vein is distended. In patients with sinus rhythm, a prominent a wave is noted, which reflects increased right atrial pressure from pulmonary hypertension and right ventricular failure. Prominent v wave is noted in patients with significant tricuspid regurgitation.
  • The apical impulse may be laterally displaced or may not be felt, especially in cases of severe mitral stenosis. This can be explained by the decreased left ventricular filling. However, a right ventricular heave can be palpated because the enlarged left atrium displaces the right ventricle anteriorly. Sometimes, a diastolic thrill can be felt at the apex with the patient in the left lateral recumbent position.
  • The auscultatory findings characteristic of mitral stenosis are a loud first heart sound, an opening snap, and a diastolic rumble.
    • The first heart sound is accentuated because of a wide closing excursion of the mitral leaflets. The degree of loudness of the first heart sound depends on the pliability of the mitral valve. The intensity of the first heart sound diminishes as the valve becomes more fibrotic, calcified, and thickened.
    • The second heart sound is closely split, and the pulmonic component is accentuated secondary to pulmonary hypertension. The opening snap follows the second heart sound. The sudden tensing of the valve leaflets after they have completed their opening excursion causes an opening snap. In patients with elevated left atrial pressure and hence with severe mitral stenosis, the opening snap occurs closer to the second heart sound.
    • The diastolic murmur of mitral stenosis is of low pitch, rumbling in character, and best heard at the apex with the patient in the left lateral position. It commences after the opening snap and the duration of the murmur correlates with the severity of the stenosis. It is absent in persons with severe disease. The murmur is accentuated by exercise, cough, and amyl nitrate, whereas it decreases with rest and with Valsalva maneuver.
  • Diastolic murmurs secondary to pulmonary regurgitation and aortic regurgitation might be present.

Causes

See Background.



Cor Triatriatum

Other Problems to be Considered

Valvulitis caused by rheumatologic conditions (eg, systemic lupus erythematosus, rheumatoid arthritis)
Massive annular calcification
Carcinoid syndrome



Lab Studies

  • Perform routine baseline tests such as CBC count, electrolyte status, and renal and liver function tests.

Imaging Studies

  • Chest radiographic findings suggestive of mitral stenosis include left atrial enlargement (eg, double shadow in right cardiac silhouette, straightening of left cardiac border due to the large left atrial appendage), prominent pulmonary vessels, redistribution of pulmonary vasculature to the upper lobes, mitral valve calcification, and interstitial edema (Kerley A and B lines).
  • Echocardiography (ECG) is the most specific and sensitive method of diagnosing and quantifying the severity of mitral stenosis. Using a transthoracic 2-dimensional echocardiogram, Doppler study, and color-flow Doppler imaging, the anatomic abnormalities of the stenotic valve (ie, thickening, mobility, diastolic doming especially of the anterior leaflet, restricted motion usually of the posterior leaflet, calcification, involvement of the subvalvular apparatus and the characteristic fusion of the commissures are usually well defined.
    • On echocardiography, the mitral valve area can be clearly visualized, and the size of the orifice can be precisely quantified. Important information about the ventricular and atrial chamber sizes, the presence of a left atrial thrombus, measurement of transvalvular gradient, and pulmonary arterial pressure can also be obtained.

    • With the use of Doppler echocardiography, sufficient information can be obtained to develop a therapeutic plan, and, consequently, most patients do not require invasive procedures such as cardiac catheterization.

    • Transesophageal echocardiography (TEE) provides better quality images and is more accurate in the measurement of left atrial appendage thrombus.

Other Tests

  • In persons with moderate-to-severe mitral stenosis, ECG shows signs of left atrial enlargement (P wave duration in lead II >0.12 seconds, P wave axis of +45° to -30°, marked terminal negative component to the P wave in V1 [1 mm wide and 1 mm deep]) and, commonly, atrial fibrillation. The mean QRS axis in the frontal plane is greater than 80°, and an R-to-S ratio of greater than 1 in lead V1 indicates the presence of right ventricular hypertrophy. As the severity of the pulmonary hypertension increases, the mean QRS axis in the frontal plane moves toward the right.

Procedures

  • Cardiac catheterization was formerly a routine procedure used to assess the severity of mitral stenosis. However, the accuracy of echocardiographic findings has resulted in only selective use of catheterization. Cardiac catheterization is now indicated in the following situations:
    • When a discrepancy exists between clinical and echocardiographic findings
    • In patients with associated severe lung disease and pulmonary hypertension in whom the contribution that mitral stenosis has to their symptoms needs to be distinguished
    • In patients in whom left atrial myxoma must be excluded
    • In men older than 40 years and women older than 50 years who have risk factors for coronary artery disease or a positive stress test result, performing a coronary angiogram is useful.
    • In patients with angina pectoris or coronary risk factors, a preoperative coronary angiogram helps determine if the patient needs a coronary bypass at the time of surgery.
    • In patients who underwent mitral valvotomy and developed serious symptoms



Medical Care

The goals of medical treatment are to reduce the recurrence of rheumatic fever, provide prophylaxis for infective endocarditis, reduce the symptoms of pulmonary congestion (eg, orthopnea, paroxysmal nocturnal dyspnea), control the ventricular rate in patients with atrial fibrillation, and prevent thromboembolic complications.

  • Asymptomatic patients with mitral valve disease must receive secondary prophylaxis against beta-hemolytic streptococci (benzathine penicillin G 1.2 million U IM q3-4 wk) for their lifetime to prevent the recurrence of rheumatic fever. They also need to receive prophylaxis for infective endocarditis prior to surgical or dental procedures.


  • Initial symptoms of pulmonary congestion are secondary to increased left atrial pressure, which can be safely reduced by diuretics. Dietary sodium restriction and nitrates that can decrease preload can be of additional use. Careful use of beta-blockers in patients with a normal sinus rhythm can prolong the diastolic filling time and thus decrease left atrial pressure. Do not use afterload reducers because they can cause hypotension mainly due to the inability to compensate through an increase in cardiac output through a stenotic valve.


  • Atrial fibrillation is common in mitral stenosis and leads to a rapid ventricular rate. An increased ventricular rate in atrial fibrillation markedly reduces diastolic filling time and increases left atrial pressure. It can be controlled by intravenous beta-blocker or calcium channel blocker therapy (diltiazem or verapamil). The rate can be controlled long-term with beta-blockers, calcium channel blockers, or digoxin.


  • Recent-onset atrial fibrillation (<6 mo) in a patient with mild mitral stenosis and normal atrial size can be easily converted to a sinus rhythm either pharmacologically or with electrical counter shock. For this purpose, anticoagulation therapy should be given for at least 3 weeks prior to cardioversion or an abbreviated route can be used once the patient is anticoagulated. A TEE can be performed to exclude the presence of left atrial thrombus. If no thrombus is present, immediate cardioversion can be performed.


  • Patients who are successfully converted to sinus rhythm need to receive long-term anticoagulation and antiarrhythmic drugs.


  • Patients who are in sinus rhythm and have systemic embolization receive anticoagulation for at least 1 year, and patients with atrial fibrillation receive anticoagulation for life.
  •  

  • Surgical correction of the mitral valve is indicated if embolization is recurrent.

Surgical Care

Surgical therapy for mitral stenosis consists of mitral valvotomy, which can be either surgical or percutaneous. The surgical approach can be through an open or closed technique; however, currently, the latter is rarely used and has been replaced by the percutaneous technique.

Asymptomatic patients with moderate or severe mitral stenosis (mitral valve area <1.5 cm2) with a suitable valve should be considered for percutaneous valvotomy if the pulmonary pressure is 50 mm Hg and above at rest or 60 mm Hg and above with exercise, or pulmonary capillary wedge pressure is 25 mm Hg and above with exercise.

Symptomatic patients with moderate or severe mitral stenosis (mitral valve area <1.5 cm2) who have suitable valves are candidates for percutaneous valvotomy.

If percutaneous valvotomy is not an option, patients should be referred for surgical repair or mitral valve replacement when they develop class III or IV symptoms.

  • Percutaneous balloon valvotomy
    • Percutaneous valvotomy is the procedure of choice for patients with uncomplicated mitral stenosis. Patients with pliable, mobile, relatively thin, minimally calcified mitral leaflets with minimal or no subvalvular stenosis are good candidates for this procedure. A TEE should be performed prior to valvotomy to clearly define the anatomy.

    • A catheter is directed into the left atrium after transseptal puncture, and a balloon is directed across the valve and inflated in the orifice. This results in separation of the mitral leaflets. The valve size is increased by approximately 2 cm2.

    • Improvement in symptoms is dramatic immediately following the procedure. When only a little symptomatic improvement occurs after valvotomy, the valvotomy was likely ineffective or mitral regurgitation was present.

    • The short- and long-term prognoses are good compared with surgical valvuloplasty. Even the long-term prognosis is good. Nearly half of all patients who undergo valvotomy require reoperation within 10 years.

    • Balloon valvotomy offers certain distinct advantages to surgical commissurotomy, which include avoidance of thoracotomy, general anesthesia, and blood transfusion.

    • The major contraindications are the presence of thrombus in the left atrium or its appendage and patients with mitral regurgitation that is more severe than grade 2.

    • Complications of a balloon mitral valvotomy include embolization, mitral regurgitation, ventricular rupture, residual atrial septal defect, and death.
  • Surgical valvotomy
    • Open surgical commissurotomy has no advantages over closed commissurotomy.
    • Surgery allows direct visualization of the mitral valve that must be repaired or replaced.
    • Using current techniques, even severe regurgitant or stenotic valves can be repaired, with good long-term results. Valves that are not suitable for repair can be replaced using either bioprosthetic or prosthetic valves.
    • With bioprosthetic valves, the patient does not require anticoagulation; however, 20-40% of these valves fail within 10 years, secondary to structural deterioration.
    • Mechanical valves are placed in young patients who do not have any contraindications for anticoagulation, and these valves are associated with good long-term durability.
    • Patients who have chronic atrial fibrillation and who undergo mitral valve surgery can have simultaneous cox maze procedure, which helps to maintain sinus rhythm in up to 80% of the cases during the postoperative period.



The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Drug Category: Antiarrhythmics

These agents alter the electrophysiologic mechanisms responsible for arrhythmia.

Drug NameDigoxin (Lanoxicaps, Lanoxin)
DescriptionCardiac glycoside with direct inotropic effects and indirect effects on the cardiovascular system. Acts directly on cardiac muscle, increasing myocardial systolic contractions. Indirect actions result in increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increase in mean arterial pressure.
Adult Dose0.125-0.375 mg PO qd
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; beriberi heart disease, idiopathic hypertrophic subaortic stenosis, constrictive pericarditis, and carotid sinus syndrome
InteractionsIV calcium may produce arrhythmias in digitalized patients
Medications that may increase levels include alprazolam, benzodiazepines, bepridil, captopril, cyclosporine, propafenone, propantheline, quinidine, diltiazem, aminoglycosides, oral amiodarone, anticholinergics, diphenoxylate, erythromycin, felodipine, flecainide, hydroxychloroquine, itraconazole, nifedipine, omeprazole, quinine, ibuprofen, indomethacin, esmolol, tetracycline, tolbutamide, and verapamil
Medications that may decrease serum levels include aminoglutethimide, antihistamines, cholestyramine, neomycin, penicillamine, aminoglycosides, oral colestipol, hydantoins, hypoglycemic agents, antineoplastic treatment combinations (including carmustine, bleomycin, methotrexate, cytarabine, doxorubicin, cyclophosphamide, vincristine, and procarbazine), aluminum or magnesium antacids, rifampin, sucralfate, sulfasalazine, barbiturates, kaolin/pectin, and aminosalicylic acid
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsHypokalemia may reduce positive inotropic effect; hypercalcemia predisposes patient to digitalis toxicity; hypocalcemia can make digoxin ineffective until serum calcium levels are normal; magnesium replacement therapy must be instituted in patients with hypomagnesemia to prevent digitalis toxicity; patients with incomplete AV block may progress to complete block when treated with digoxin; exercise caution in hypothyroidism, hypoxia, and acute myocarditis; adjust dose in renal impairment; highly toxic (overdoses can be fatal)

Drug NameAmiodarone (Cordarone, Pacerone)
DescriptionMay inhibit AV conduction and sinus node function. Prolongs action potential and refractory period in myocardium and inhibits adrenergic stimulation. Prior to administration, control ventricular rate and CHF (if present) with digoxin or calcium channel blockers.
Adult DoseLoading dose: 800-1600 mg/d PO in 1-2 doses for 1-3 wk; decrease to 600-800 mg/d in 1-2 doses for 1 mo
Maintenance dose: 400 mg/d PO
Alternatively: 150 mg (10 mL) IV over first 10 min, followed by 360 mg (200 mL) over next 6 h, then 540 mg over next 18 h
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; complete AV block; intraventricular conduction defects; patients taking ritonavir or sparfloxacin
InteractionsIncreases effect and blood levels of theophylline, quinidine, procainamide, phenytoin, methotrexate, flecainide, digoxin, cyclosporine, beta-blockers, and anticoagulants; cardiotoxicity is increased by ritonavir, sparfloxacin, and disopyramide; coadministration with calcium channel blockers may cause additive effect and further decrease myocardial contractility; cimetidine may increase levels; protease inhibitors (eg, indinavir, ritonavir, amprenavir, nelfinavir) inhibit metabolism, resulting in increased serum levels, and may prolong QT interval
PregnancyD - Unsafe in pregnancy
PrecautionsCaution in thyroid or liver disease

Drug Category: Calcium channel blockers

In specialized conducting and automatic cells in the heart, calcium is involved in the generation of the action potential. Calcium channel blockers inhibit movement of calcium ions across the cell membrane, depressing both impulse formation (automaticity) and conduction velocity.

Drug NameDiltiazem (Cardizem CD, Dilacor, Tiazac, Cardizem LA)
DescriptionDuring depolarization, inhibits calcium ions from entering slow channels and voltage-sensitive areas of vascular smooth muscle and myocardium.
Adult DoseCardizem SR: 60-120 mg PO bid
Cardizem CD: 180-240 mg PO qd in hypertension
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; severe CHF; sick sinus syndrome; second- or third-degree AV block; hypotension (<90 mm Hg systolic)
InteractionsMay increase carbamazepine, digoxin, cyclosporine, and theophylline levels; when administered with amiodarone, may cause bradycardia and a decrease in cardiac output; when given with beta-blockers, may increase cardiac depression; cimetidine may increase levels
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in impaired renal or hepatic function; may increase LFT levels, and hepatic injury may occur

Drug Category: Anticoagulants

These agents prevent recurrent or ongoing thromboembolic occlusion of the vertebrobasilar circulation.

Drug NameWarfarin (Coumadin)
DescriptionInterferes with hepatic synthesis of vitamin K–dependent coagulation factors. Used for prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders. Tailor dose to maintain an INR of 2-3.
Adult Dose5-15 mg/d PO qd for 2-5 d; adjust dose according to desired INR
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; severe liver or kidney disease; open wounds or GI ulcers
InteractionsDrugs that may decrease anticoagulant effects include griseofulvin, carbamazepine, glutethimide, estrogens, nafcillin, phenytoin, rifampin, barbiturates, cholestyramine, colestipol, vitamin K, spironolactone, oral contraceptives, and sucralfate
Medications that may increase anticoagulant effects include oral antibiotics, capecitabine, phenylbutazone, salicylates, sulfonamides, chloral hydrate, clofibrate, diazoxide, anabolic steroids, ketoconazole, ethacrynic acid, miconazole, nalidixic acid, sulfonylureas, allopurinol, chloramphenicol, cimetidine, disulfiram, metronidazole, phenylbutazone, phenytoin, propoxyphene, sulfonamides, gemfibrozil, acetaminophen, and sulindac
PregnancyX - Contraindicated in pregnancy
PrecautionsDo not switch brands after achieving therapeutic response; caution in active tuberculosis or diabetes; patients with protein C or S deficiency are at risk of developing skin necrosis

Drug NameHeparin
DescriptionAugments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. Does not actively lyse but is able to inhibit further thrombogenesis. Prevents reaccumulation of clot after spontaneous fibrinolysis.
Adult DoseInitial dose: 40-170 U/kg IV
Maintenance infusion: 18 U/kg/h IV
Alternatively: 50 U/kg/h IV initially, followed by continuous infusion of 15-25 U/kg/h; increase dose by 5 U/kg/h q4h prn using aPTT results
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; subacute bacterial endocarditis; active bleeding; history of heparin-induced thrombocytopenia
InteractionsDigoxin, nicotine, tetracycline, and antihistamines may decrease effects; NSAIDs, aspirin, dextran, dipyridamole, and hydroxychloroquine may increase heparin toxicity
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsIn neonates, preservative-free heparin is recommended to avoid possible toxicity (gasping syndrome) from benzyl alcohol, which is used as a preservative; caution in severe hypotension and shock; monitor for bleeding in peptic ulcer disease, menstruation, increased capillary permeability, and when giving IM injections

Drug Category: Beta-adrenergic blockers

These agents inhibit chronotropic, inotropic, and vasodilatory responses to beta-adrenergic stimulation.

Drug NameMetoprolol (Lopressor, Toprol XL)
DescriptionSelective beta1-adrenergic receptor blocker that decreases automaticity of contractions. During IV administration, carefully monitor blood pressure, heart rate, and ECG.
Adult Dose100 mg/d PO qd or divided bid/tid initially; increase at 1-wk intervals prn, not to exceed total of 450 mg/d
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; uncompensated congestive heart failure; bradycardia, asthma; cardiogenic shock; AV conduction abnormalities
InteractionsAluminum salts, barbiturates, NSAIDs, penicillins, calcium salts, cholestyramine, and rifampin may decrease bioavailability and plasma levels, possibly resulting in decreased pharmacologic effects; toxicity may increase with coadministration of sparfloxacin, phenothiazines, astemizole, calcium channel blockers, quinidine, flecainide, and contraceptives; may increase toxicity of digoxin, flecainide, clonidine, epinephrine, nifedipine, prazosin, verapamil, and lidocaine
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsPregnancy category D in second or third trimester; beta-adrenergic blockade may reduce signs and symptoms of acute hypoglycemia and may decrease clinical signs of hyperthyroidism; abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm; monitor patient closely and withdraw drug slowly; during IV administration, carefully monitor blood pressure, heart rate, and ECG

Drug Category: Antibiotics

Must cover all likely pathogens in the context of this clinical setting. Use as prophylaxis against streptococcal infections.

Drug NamePenicillin G benzathine (Bicillin L-A, Permapen)
DescriptionInterferes with synthesis of cell wall mucopeptides during active multiplication, which results in bactericidal activity. Used to treat syphilis and for prophylaxis of recurrent streptococcal infections.
Adult Dose2 million U IM qmo
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid can increase effectiveness by decreasing clearance; coadministration with tetracyclines can decrease effectiveness
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsCaution in impaired renal function

Drug Category: Diuretics

Diuretics are used for treatment of pulmonary congestion. Treatment may improve symptoms of venous congestion through elimination of retained fluid and preload reduction.

Drug NameFurosemide (Lasix)
DescriptionIncreases excretion of water by interfering with chloride-binding cotransport system, which, in turn, inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. Dose must be individualized to patient. Depending on response, administer at increments of 20-40 mg, no sooner than 6-8 h after previous dose, until desired diuresis occurs. When treating infants, titrate with increments of 1 mg/kg/dose until a satisfactory effect is achieved.
Adult Dose20-80 mg/d PO/IV/IM; titrate up to 600 mg/d for severe edematous states
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; hepatic coma; anuria; state of severe electrolyte depletion
InteractionsMetformin decreases concentrations; interferes with hypoglycemic effect of antidiabetic agents and antagonizes muscle-relaxing effect of tubocurarine; auditory toxicity appears to be increased with coadministration of aminoglycosides; hearing loss of varying degrees may occur; anticoagulant activity of warfarin may be enhanced when taken concurrently; increased plasma lithium levels and toxicity are possible when taken concurrently
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsPerform frequent serum electrolyte, carbon dioxide, glucose, creatinine, uric acid, calcium, and BUN determinations during first few months of therapy and periodically thereafter



Media file 1:  M-mode across the mitral valve showing a flat E-F slope resulting from elevated left atrial pressure throughout diastole due to a significant gradient across the mitral valve. Increased thickness and calcification of anterior leaflet of the mitral valve and decreased opening of the anterior and posterior leaflets in diastole are also shown.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image

Media file 2:  Parasternal long-axis view demonstrating calcification and doming in diastole of the anterior valve leaflet and mild restriction in the opening of posterior mitral valve leaflet.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image

Media file 3:  Apical 4-chamber view demonstrating restricted opening of the anterior and posterior mitral valve leaflet with diastolic doming of anterior leaflet with left atrial enlargement.
Click to see larger pictureClick to see detailView Full Size Image
 
Media type:  Video

Media file 4:  Transesophageal echocardiogram with continuous wave Doppler interrogation across the mitral valve demonstrating an increased mean gradient of 16 mm Hg consistent with severe mitral stenosis.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Image

Media file 5:  Apical 4-chamber view with color Doppler demonstrating aliasing in the atrial side of the mitral valve consistent with increased gradient across the valve. This figure also shows mitral regurgitation and left atrial enlargement.
Click to see larger pictureClick to see detailView Full Size Image
 
Media type:  Video

Media file 6:  Magnified view of the mitral valve in apical 4-chamber view revealing restricted opening of both leaflets.
Click to see larger pictureClick to see detailView Full Size Image
 
Media type:  Video

Media file 7:  Transesophageal echocardiogram in an apical 3-chamber view showing calcification and doming of the anterior mitral leaflet and restricted opening of both leaflets.
Click to see larger pictureClick to see detailView Full Size Image
 
Media type:  Video

Media file 8:  Transesophageal echocardiogram in an apical 3-chamber view with color Doppler interrogation of the mitral valve revealing aliasing, which is consistent with increased gradient across the mitral valve secondary to stenosis. Also shown in this image, a posteriorly directed jet of severe mitral regurgitation.
Click to see larger pictureClick to see detailView Full Size Image
 
Media type:  Video



  • Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. Aug 1 2006;114(5):e84-231.
  • Bonow RO, Braunwald E. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. In: Valvular Heart. Chap 57. Philadelphia, Pa: WB Saunders;2005: 1553-1602.
  • Bruce CJ, Nishimura RA. Newer advances in the diagnosis and treatment of mitral stenosis. Curr Probl Cardiol. Mar 1998;23(3):125-92. [Medline].
  • Carabello BA. Modern management of mitral stenosis. Circulation. Jul 19 2005;112(3):432-7. [Medline].
  • Feldman T. Rheumatic Mitral Stenosis. Curr Treat Options Cardiovasc Med. Apr 2000;2(2):93-104.
  • Horstkotte D, Niehues R, Strauer BE. Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis. Eur Heart J. Jul 1991;12 Suppl B:55-60. [Medline].
  • Marcus RH, Sareli P, Pocock WA, et al. The spectrum of severe rheumatic mitral valve disease in a developing country. Correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann Intern Med. Feb 1 1994;120(3):177-83. [Medline].

Mitral Stenosis excerpt

Article Last Updated: Jan 3, 2007